Effect of Kamsaharitaki on Bronchial Asthma

Phase 2

Completed

• Conditions: Health Condition 1: J453- Mild persistent asthma

• Registration Number: CTRI/2021/01/030639
• Lead Sponsor: Director

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2022-02-17
• Last Update Posted: 1 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 61

Inclusion Criteria

1. Patients presenting with minimum 3 to 4 classical signs and symptoms of Tamaka Shwasa.

2. Mild persistent cases of asthma (as per WHO GINA guidelines) of duration more than 6 months.

Exclusion Criteria

1.Age more than 60 years and below 18years.

2.Mild intermittent, moderated persistent, severe persistent to severe asthma.

3.Dyspnoea resulting from other diseases like left ventricular failure, COPD (chronic bronchitis, emphysema), upper respiratory tract obstruction, bronchiectasis, etc.

4.Patients on regular steroidal therapy, inhalers or bronchodilators.

5.Patients having pneumonia, tuberculosis, lung cancer, lung abscess and another such complicated conditions.

6.Patients having diabetes, hypertension, acute and chronic renal failure etc. conditions in which urination is markedly diminished or excessive were excluded.

7.HIV positive patients.

8.Pregnant/lactating mothers

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.To validate SMP of Kamsaharitaki Avaleha. <br/ ><br>2.To validate therapeutic efficacy of Kamsaharitaki Avaleha. <br/ ><br>Timepoint: 28 days <br/ ><br>

Secondary Outcome Measures

Name	Time	Method
To establish the role of two varieties(Abhaya and Vijaya) of Haritaki in Kamsaharitaki AvalehaTimepoint: 28 days